Journals / Turkish Journal of Pharmaceutical Sciences / 2022 / Cilt: 19 - Sayı: 1

WLBU2 Antimicrobial Peptide as a Potential Therapeutic for Treatment of Resistant Bacterial Infections

Dirençli Bakteriyel Enfeksiyonların Tedavisinde Potansiyel Bir Terapötik Olarak WLBU2 Antimikrobiyal Peptit

Pages
110–115
Publication Date
2022-11-02
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this review we highlight the evidence supporting the promising properties of WLBU2 as an antibacterial agent with potential applications for the treatment of infections caused by resistant bacteria

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Antimicrobial resistance is considered a major health problem, worldwide.
📊
Key Findings & Data:It is significantly associated with high morbidity and mortality rates.
💡
Conclusion & Impact:In this review we highlight the evidence supporting the promising properties of WLBU2 as an antibacterial agent with potential applications for the treatment of infections caused by resistant bacteria
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Antimicrobial resistance is considered a major health problem, worldwide. It is significantly associated with high morbidity and mortality rates. The current antibiotics have limited therapeutic efficacy in providing treatment for multidrug resistant bacteria. Accordingly, research in the antimicrobial field has been directed toward the discovery of new agents to overcome bacterial resistance. Antimicrobial peptides (AMP) have been extensively studied as potential antimicrobial agents with lower incidence of drug resistance compared to conventional antibiotics. WLBU2 is an engineered cationic AMP with promising antibacterial activity. It is composed of 24 amino acids including; 13 arginine, 8 valine and 3 tryptophan residues. Findings from in vitro and in vivo studies showed that WLBU2 is a potent peptide with a broad spectrum activity against Gram-positive, Gram-negative, multidrug resistant, and biofilm forming bacteria. Additionally, WLBU2 appears as a salt-resistant peptide with potential application for treatment of infections at conditions with disturbed normal salt homeostasis. Furthermore, WLBU2 was found as AMP with limited host toxicity. Recent investigations have shown that combination of WLBU2 with conventional antibiotics can result in synergism against resistant bacteria. In this review we highlight the evidence supporting the promising properties of WLBU2 as an antibacterial agent with potential applications for the treatment of infections caused by resistant bacteria

Özet

Antimikrobiyal direnç, dünya çapında önemli bir sağlık sorunu olarak kabul edilmektedir. Yüksek morbidite ve mortalite oranları ile önemli oranda ilişkilidir. Mevcut antibiyotikler, çoklu ilaca dirençli bakterilerin tedavisini sağlamada sınırlı terapötik etkinliğe sahiptir. Bu nedenle, antimikrobiyal alanda yapılan araştırmalar, bakteriyel direncin ortadan kaldırmak için yeni ajanların keşfedilmesine yöneliktir. Antimikrobiyal peptitler (AMP), geleneksel antibiyotiklere kıyasla daha düşük ilaç direnci insidansına sahip potansiyel antimikrobiyal ajanlar olarak kapsamlı bir şekilde incelenmiştir. WLBU2, umut verici antibakteriyel aktiviteye sahip, tasarlanmış bir katyonik AMP’dir. On üç arjinin, 8 valin ve 3 triptofan rezidülerini içeren 24 amino asitten meydana gelmektedir. İn vitro ve in vivo çalışmalardan elde edilen bulgular, WLBU2’nin Gram-pozitif, Gram-negatif, çoklu ilaç direnci ve biyofilm oluşturan bakterilere karşı geniş spektrumlu aktiviteye sahip güçlü bir peptit olduğunu göstermektedir. Ayrıca, WLBU2, normal tuz homeostazı bozulmuş koşullarda enfeksiyonların tedavisi için potansiyel uygulamayla tuza dirençli bir peptit olarak görünmektedir. Dahası, WLBU2 sınırlı konakçı toksisitesine sahip AMP olarak bulunmuştur. Son araştırmalar, WLBU2’nin geleneksel antibiyotiklerle kombinasyonunun dirençli bakterilere karşı sinerjizm ile sonuçlanabileceğini göstermiştir. Bu derlemede, dirençli bakterilerin neden olduğu enfeksiyonların tedavisi için potansiyel uygulamaları olan bir antibakteriyel ajan olarak WLBU2’nin umut verici özelliklerini destekleyen kanıtları vurguluyoruz.

🔖

Cite This Article

ELSALEM, L., KHASAWNEH, A., SHEBOUL, S. A. (2022). WLBU2 Antimicrobial Peptide as a Potential Therapeutic for Treatment of Resistant Bacterial Infections. Turkish Journal of Pharmaceutical Sciences, Cilt: 19 - Sayı: 1, 110–115. https://ajindex.com/articles/613591

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Ferri M, Ranucci E, Romagnoli P, Giaccone V. Antimicrobial resistance: A global emerging threat to public health systems. Crit Rev Food Sci Nutr. 2017;57:2857-2876
  2. Prestinaci F, Pezzotti P, Pantosti A. Antimicrobial resistance: a global multifaceted phenomenon. Pathog Glob Health. 2015;109:309-318. 3. https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar- threats-report-508.pdf 4. No Time to Wait: Securing the future from drug-resistant infections. UN Interagency Coordination Group (IACG) on Antimicrobial Resistance, 2019
  3. Dadgostar P. Antimicrobial resistance: implications and costs. Infect Drug Resist. 2019;12:3903-3910
  4. Thabit AK, Crandon JL, Nicolau DP. Antimicrobial resistance: impact on clinical and economic outcomes and the need for new antimicrobials. Expert Opin Pharmacother. 2015;16:159-177
  5. Gajdács M. The continuing threat of methicillin-resistant Staphylococcus aureus. Antibiotics (Basel). 2019;8:52
  6. Harkins CP, Pichon B, Doumith M, Parkhill J, Westh H, Tomasz A, de Lencastre H, Bentley SD, Kearns AM, Holden MTG. Methicillin- resistant Staphylococcus aureus emerged long before the introduction of methicillin into clinical practice. Genome Biol. 2017;18:130
  7. Mutters NT, Günther F, Sander A, Mischnik A, Frank U. Influx of multidrug-resistant organisms by country-to-country transfer of patients. BMC Infect Dis. 2015;15:466
  8. Kshetry AO, Pant ND, Bhandari R, Khatri S, Shrestha KL, Upadhaya SK, Poudel A, Lekhak B, Raghubanshi BR. Minimum inhibitory concentration of vancomycin to methicillin resistant Staphylococcus aureus isolated from different clinical samples at a tertiary care hospital in Nepal. Antimicrob Resist Infect Control. 2016;5:27
  9. McGuinness WA, Malachowa N, DeLeo FR. Vancomycin resistance in Staphylococcus aureus. Yale J Biol Med. 2017;90:269-281
  10. Perl TM. The threat of vancomycin resistance. Am J Med. 1999;106:26S-37S; discussion 48S-52S
  11. Centers for Disease Control and Prevention (CDC). Staphylococcus aureus resistant to vancomycin--United States, 2002. MMWR Morb Mortal Wkly Rep. 2002;51:565-567
  12. Exner M, Bhattacharya S, Christiansen B, Gebel J, Goroncy-Bermes P, Hartemann P, Heeg P, Ilschner C, Kramer A, Larson E, Merkens W, Mielke M, Oltmanns P, Ross B, Rotter M, Schmithausen RM, Sonntag HG, Trautmann M. Antibiotic resistance: what is so special about multidrug-resistant Gram-negative bacteria? GMS Hyg Infect Control. 2017;12:Doc05
  13. Kaye KS, Pogue JM. Infections caused by resist